IP Library › Granted Patent US 7,358,277
Granted Patent B2
US 7,358,277 · App. 10/484,476 · Granted Apr 15, 2008

Use of a lactate salt for the treatment and prophylaxis of atherosclerosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,358,277
App. No.
10/484,476
Granted
Apr 15, 2008
Kind
B2
Abstract

The use of a lactate metal salt, in particular an L-lactate, for the treatment of atheroscloerosis and/or for the prophylaxis or treatment of diseases caused by atherosclerosis is disclosed.

Claims (13)

1. A method for the treatment of atherosclerosis or diseases caused by atherosclerosis in a subject, comprising administering to the subject a pharmaceutical composition comprising calcium lactate, wherein calcium lactate is present as the only effective anti-atherosclerosis agent and the only effective agent against diseases caused by atherosclerosis.

2. A method for the treatment of atherosclerosis in a subject, comprising administering to the subject a pharmaceutical composition comprising calcium lactate, wherein calcium lactate is present as the only effective anti-atherosclerosis agent.

3. A method for the treatment of diseases caused by atherosclerosis in a subject comprising administering to the subject a pharmaceutical composition comprising calcium lactate, wherein calcium lactate is present as the only effective agent against diseases caused by atherosclerosis.

4. The method according to any one of claims 1 or 2 - 3 , wherein the lactate is L-lactate.

5. The method according to any one of claims 1 or 2 - 3 , wherein the composition is micro-encapsulated.

6. The method according to any one of claims 1 or 2 - 3 , wherein the composition is for oral administration.

7. The method according to any one of claims 1 or 2 - 3 , wherein the composition is administered at a daily dose of between 2.0 g and 6.0 g of lactate.

8. The method according to claim 1 or claim 3 , wherein the diseases caused by atherosclerosis are coronary heart diseases.

9. The method according to any one of claims 1 or 2 - 3 , wherein the composition further contains additives suitable for preparing food, especially dietetic food or food supplements.

10. The method according to any one of claims 1 or 2 - 3 , wherein the composition further comprises pharmaceutically acceptable additives and/or corners.

11. The method according to any one of claims 1 or 2 - 3 , wherein the composition is present in solid farm as a lozenge, powder or granulate or in liquid form as a syrup or juice.

12. The method according to any one of claims 1 or 2 - 3 , wherein the daily dose is between 3.0 g and 5.0 g of lactate.

13. The method according to any one of claims 1 or 2 - 3 , wherein the daily dose is 4.0 of lactate.